RazorSharpDNA 🧬 (@RazorSharpDNA) header
RazorSharpDNA 🧬 (@RazorSharpDNA) profile picture

Biotech, explained by the science 🧬 Gene editing, readouts, M&A, AI firsts, longevity, psychedelics. Primary sources, honest caveats. Not 💵 advice.

Joined November 2011
Photo by RazorSharpDNA 🧬 (@RazorSharpDNA)Photo by RazorSharpDNA 🧬 (@RazorSharpDNA)Photo by RazorSharpDNA 🧬 (@RazorSharpDNA)Photo by RazorSharpDNA 🧬 (@RazorSharpDNA)Photo by RazorSharpDNA 🧬 (@RazorSharpDNA)Photo by RazorSharpDNA 🧬 (@RazorSharpDNA)Photo by RazorSharpDNA 🧬 (@RazorSharpDNA)Photo by RazorSharpDNA 🧬 (@RazorSharpDNA)Photo by RazorSharpDNA 🧬 (@RazorSharpDNA)Photo by RazorSharpDNA 🧬 (@RazorSharpDNA)
Biotech, explained by the science. Gene editing, clinical readouts, M&A, AI and robotics firsts, longevity and psychedelic medicines. Hard numbers, honest caveats. 🧬
173
Depression scores split from placebo by Day 2, and the gap held to Week 12. $HELP HLP003 (deuterated psilocin) on top of an antidepressant, Phase 3, 222 patients: MADRS 7.6 points better at Week 6, remission 50.9% vs 18.2%. Second pivotal reads 4Q 2027. Will it replicate?
3
4
218
3 of 4 evaluable patients gained retinal sensitivity on the low dose of a retinal gene therapy. $IRD OPGx-BEST1, BIRD-1 cohort 1: structural gains in 4 of 5, no SAEs. High dose (11 dosed) reads out Q1 2027. Open label, 5 patients. Does dose widen it?
1
75
Median survival 24.0 vs 14.7 months from a peptide vaccine in relapsed AML. $SLS galinpepimut-S, Phase 3 REGAL (126 patients, second remission, no transplant): HR 0.59, p=0.035 at 80 deaths. Mostly mild injection site reactions. Open label, thin p. Do the secondaries hold?
1
1
2
293
Weight lost on semaglutide alone was 68% fat, 32% lean. With enobosarm 3 mg added, it was 100% fat. $VERU QUALITY post hoc, age 65+ (n=29 vs 30), 16 weeks: stair climb power +16.5% and climb time −16.3%, placebo corrected. Caveat: post hoc subset. Does PLATEAU confirm it?
1
120
Source: planion.events/e/tos/ow2026/… (Oral-115, podium Mon Nov 16 5:15 PM ET).
39
5.0% weight loss at 12 wks from a CB1 inverse agonist built to stay out of the brain. $CRBP CRB-913, CANYON-1 (n=254, 20/40/60 mg): irritability 6.2/8.2/9.7% vs 0%, anxiety 3.1/8.2/4.8% vs 4.5%, depression 0/0/1.6% vs 0% placebo. Caveat: 12 wks. Did peripheral restriction hold?
1
1
335
14.3% less visceral fat from one shot, while lean mass rose 2.4%. $WVE WVE-007 (GalNAc siRNA silencing INHBE), Phase 1 INLIGHT interim at ObesityWeek: single 240 mg dose, placebo adjusted, month 6 DEXA. 🧵
1
466
4/ Caveats: single ascending dose, 3:1 randomization, small arms, March 2026 interim cut, and the 240 and 400 mg groups differed at baseline (BMI 32.1 vs 30.9). No serious TEAEs or discontinuations through 600 mg. Does fat quality matter if the scale barely moves?
1
114
80% mean drop in non-sustained VT in the 7 high-dose patients. $LXEO LX2020, an AAV gene therapy restoring PKP2 in arrhythmogenic cardiomyopathy, Phase I/II: PVC burden down 44%. FDA is open to NSVT as a pivotal surrogate. Open label and small. Will it hold up?
1
1
537
Aficamten beat metoprolol head to head: peak VO2 +1.1 vs −1.2 mL/kg/min at 24 weeks (difference 2.3, p<0.001, 175 patients). $CYTK MYQORZO label now includes MAPLE-HCM. Indication unchanged; boxed heart failure warning and REMS stay. Enough to move it ahead of beta blockers?
$CYTK FDA Approves sNDA to Update Prescribing Information for MYQORZO (aficamten) to Include Data from Phase 3 MAPLE-HCM
1
356
RazorSharpDNA 🧬 retweeted
11
96
1
920
17,948
At least 90% of patients were attack free in every month for up to four years after one CRISPR infusion. $NTLA lonvo-z 50 mg Phase 1/2 HAE follow up at ACAAI: 32 patients, 100% off long term prophylaxis. Phase 3 HAELO cut monthly attacks 87% vs placebo. PDUFA by Mar 10 2027. Small open label cohort.
2
10
1,099